Now, Moderna Says Its Vaccine Is 94.5% Effective in Preventing COVID-19

Rodiano Bonacci
Novembre 18, 2020

The analysis was conducted after 20 participants developed the virus and examined how many had received the vaccine versus a placebo.

Moderna's data provide further validation of the promising but previously unproven mRNA platform, which turns the human body into a vaccine factory by coaxing cells to make certain virus proteins that the immune system sees as a threat and mounts a response against.

Moderna expects the vaccine to be stable at normal fridge temperatures of 2-8C (36-48°F) for 30 days and it can be stored for up to six months at -20C.

Moderna expects to have enough safety data required for USA authorisation in the next week or so and expects to file for emergency use authorisation (EUA) in the coming weeks.

Pfizer's vaccine must be shipped and stored at -70 degrees Celsius, the sort of temperature typical of an Antarctic winter.

Pfizer said it would continue its trial until there were 164 Covid-19 registered cases.

Next year, the US government could have access to more than 1 billion doses just from the two vaccine makers, more than needed for the country's 330 million residents.

As part of Operation Warp Speed, the federal government in the U.S. signed an agreement with Pfizer in July for up to 600 million doses of the Covid-19 vaccine.

"Assuming we get an emergency use authorization, we'll be ready to ship through Warp Speed nearly in hours", Hoge said. 'So it could start being distributed instantly.

One unknown with this vaccine, and all the others now being tested, is whether they will stop COVID-19 spreading.

Most side effects were mild to moderate. Most of these complaints were generally short-lived, the company said.

The Trump Administration has mainly relied on the development of vaccines and treatments as its response to the pandemic. Moderna has received almost $1 billion in research and development funding from the USA government and has a $1.5 billion deal for 100 million doses.

The contract includes an option to request up to a further 180 million doses, to be supplied once a vaccine has proven to be safe and effective against Covid-19.

The company hopes to produce between 500 million and 1 billion doses in 2021, split between its United States and worldwide manufacturing sites, depending in part on demand.

Moderna also said it will use its data to seek authorisation in Europe and other regions.

In an interview to CBS on Tuesday, Azar said that Pfizer will be producing 20 million doses of the vaccine every month over the next several months.

Other countries such as China and Russian Federation have already begun vaccinations.

CureVac, a European company based in Germany, signed a €75 million loan agreement with the European Investment Bank on 6 July for the development and large-scale production of vaccines, including CureVac's vaccine candidate against Covid-19.

'The vaccine is really the light at the end of the tunnel, Dr Anthony Fauci, the top USA infectious diseases expert said.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE